CompletedPhase 4

AT1R Blockade and Periodic Breathing During Sleep in Hypoxia

Canada14 participantsStarted 2018-01-01

Plain-language summary

Sleep disordered breathing (SDB) is characterized by regular periods of no breathing (apnea) or low levels of breathing (hypopnea) and leads to repeated periods of low oxygenation, termed intermittent hypoxia that causes fluctuations in blood oxygen levels. This leads to increased peripheral chemoreflex sensitivity that is thought to occur through the stimulation of angiotensin-II, type-I receptors (AT1R) that are expressed primarily on glomus cells within the peripheral chemoreflex and ultimately results in long lasting hypertension. The goal of this study is to determine if AT1R receptor blockade can prevent the increase in chemoreflex sensitivity following one night of hypoxia and improve the severity of SDB.

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * normotensive * forced expiratory volume in 1s : forced vital capacity ratio \> 0.75 * no medical history of cardiovascular and respiratory disease * not taking medications other than oral contraceptives * free from sleep apnea * body mass index less than 30 kg/m2 Exclusion Criteria: * history of hypertension * known impaired renal function * liver disease * heart failure * myocardial infarction * coronary artery disease * smoked within the past year * apnea hypopnea index \> 5 events per hour

What they're measuring

apnea-hypopnea index

Timeframe: 8 hours

Trial details

NCT IDNCT03335904

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-08-01

View on ClinicalTrials.gov More Sleep Disordered Breathing trials